Clinical Trial Update: A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy [Phase 3]

View source ↗

Summary

A Phase III randomized trial evaluating Ceralasertib plus Durvalumab versus Docetaxel in advanced/metastatic non-small cell lung cancer after prior PD-(L)1 ther…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Ceralasertib (ceralasertib)
• DOCETAXEL (DOCETAXEL)
• Durvalumab (durvalumab)

Snippet

Sponsor: AstraZeneca | Conditions: Advanced or Metastatic Non-Small Cell Lung Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING